• Researcher Profile

    David P. Steensma, MD

    David P. Steensma, MD

    Top Doctor

    Senior Physician

    Associate Professor of Medicine, Harvard Medical School


    Hematologic Oncology
    Dana-Farber at St. Elizabeth's

    Office phone: 617-632-3712 (Boston main campus); 617-789-2903 (St. Elizabeth's)
    Fax: 617-582-7840 (Boston main campus); 617-789-2064 (St. Elizabeth's)

    Preferred contact method: office phone

    View Physician Profile

    Research Department

    Medical Oncology/Hematologic Malignancies


    Myelodysplastic syndromes, Hematologic malignancies

    Dana-Farber Cancer Institute
    450 Brookline Avenue
    Mayer 1B21
    Boston, MA 02215

    Other Practice Locations

    Dana-Farber Cancer Institute at St. Elizabeth's Medical Center
    736 Cambridge Street
    Cushing Pavilion, 5th Floor
    Brighton, MA 02135

    Recent Awards

    • Hematology/Oncology Teacher of The Year Finalist, Mayo Clinic, 2007, 2008
    • Fellowship, American College of Physicians, 2006

    Select Publications

    • Steensma DP, Baer MR, Slack JL, Buckstein R, Godley LA, Garcia-Manero G, Albitar M, Larsen JS, Arora S, Cullen MT, Kantarjian H. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: The alternative dosing for outpatient treatment (ADOPT) trial. Journal of Clinical Oncology. 2009;27(23): 3842-8.
    • Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke M, Weingart O, Kluge S, Piper M, Rades D, Steensma DP, Djulbegovic B, Fey MF, Ray-Coquard I, Machtay M, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: A meta-analysis of randomised trials. Lancet. 2009;373(9674):1532-42.
    • Steensma DP, Neiger JD, Porcher JC, Keats JJ, Bergsagel PL, Knudson RA, Jenkins RD, Santana-Davila R, Kumar R, Ketterling R. Rearrangements and amplification of IER3 (IEX-1) represent a novel and recurrent molecular abnormality in myelodysplastic syndromes (MDS). Cancer Res. 2009;69(19):7518-23.
    • Sekeres MA, Steensma DP. Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease: implications for clinical trial design and enrollment. Blood. 2009;114(13):2575-80.
    • Steensma DP. The Blood of the Lamb. Journal of Clinical Oncology. 2009;27(16):2729-31.
    • Wardrop D, Steensma DP. Is refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) a necessary or useful diagnostic category? British Journal of Haematology. 2009; 144(6):809-17.
    • Hanson CA, Steensma DP, Hodnefield JM, Nguyen PL, Hoyer JD, Viswanatha DS, Zou Y, Knudson RA, Van Dyke DL, Ketterling RP. Isolated trisomy 15: A clonal chromosome abnormality in bone marrow with doubtful hematologic significance. Am J Clin Pathol. 2008;129(3):478-85.
    • Caudill JS, Imran H, Porcher JC, Steensma DP. Congenital sideroblastic anemia associated with germline polymorphisms reducing expression of FECH. Haematologica. 2008; 93(10):1582-4.
    • Palmer SR, Tefferi A, Hanson CA, Steensma DP. Platelet count is an IPSS-independent risk factor predicting survival in refractory anaemia with ringed sideroblasts. British Journal of Haematology. 2008;140(6):722-5.
    • Steensma DP, Porcher JC, Hanson CA, Lathrop CL, Hoyer JD, Tefferi A, Lasho TL, Higgs DR. Prevalence of erythrocyte haemoglobin H inclusions in unselected patients with clonal myeloid disorders. British Journal of Haematology. 2007;139(3):439-442.
View Physician Directory

Find a Clinical Trial

Support Cancer

Give Now